The role of fibroblast growth factor 21 in diabetes and its complications: A review from clinical perspective

Diabetes Research and Clinical Practice

Volumn 108, Issue 3, 2015, Pages 382-389

  Liu, Jian Jun ^a   Foo, Joo Pin ^b   Liu, Sylvia ^a   Lim, Su Chi ^a  

^a KHOO TECK PUAT HOSPITAL   (Singapore)

^b CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

Diabetes; Diabetes complications; Diabetes therapy; Fibroblast growth factor 21

Indexed keywords

ANTIDIABETIC AGENT; FENOFIBRATE; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 21 MIMETIC; LY 2405319; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR;

BONE METABOLISM; CARDIOMETABOLIC RISK; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE RESISTANCE; DRUG SAFETY; DYSLIPIDEMIA; ENERGY METABOLISM; GROWTH INHIBITION; HUMAN; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LATENT AUTOIMMUNE DIABETES IN ADULTS; MASSIVE OSTEOLYSIS; METABOLIC REGULATION; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN RESISTANCE; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; BLOOD;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FIBROBLAST GROWTH FACTORS; HUMANS;

EID: 84930178522     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.02.032     Document Type: Review

References (66)

1. Angelin B., Larsson T.E., Rudling M. Circulating fibroblast growth factors as metabolic regulators-a critical appraisal. Cell Metab 2012, 16:693-705.
2. Nishimura T., Nakatake Y., Konishi M., Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000, 1492:203-206.
3. Woo Y.C., Xu A., Wang Y., Lam K.S. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf) 2013, 78:489-496.
4. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005, 115:1627-1635.
5. Zhang Y., Xie Y., Berglund E.D., Coate K.C., He T.T., Katafuchi T., et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. Elife 2012, 1:e00065.
6. Reitman M.L. FGF21 mimetic shows therapeutic promise. Cell Metab 2013, 18:307-309.
7. Iglesias P., Selgas R., Romero S., Diez J.J. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol 2012, 167:301-309.
8. Van Belle T.L., Gysemans C., Mathieu C. Vitamin D and diabetes: the odd couple. Trends Endocrinol Metab 2013, 24:561-568.
9. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
10. Zhang X., Yeung D.C., Karpisek M., Stejskal D., Zhou Z.G., Liu F., et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008, 57:1246-1253.
11. An S.Y., Lee M.S., Yi S.A., Ha E.S., Han S.J., Kim H.J., et al. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract 2012, 96:196-203.
12. Mraz M., Bartlova M., Lacinova Z., Michalsky D., Kasalicky M., Haluzikova D., et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009, 71:369-375.
13. Chavez A.O., Molina-Carrion M., Abdul-Ghani M.A., Folli F., Defronzo R.A., Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009, 32:1542-1546.
14. Chen C., Cheung B.M., Tso A.W., Wang Y., Law L.S., Ong K.L., et al. High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 2011, 34:2113-2115.
15. Li X., Fan X., Ren F., Zhang Y., Shen C., Ren G., et al. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diabetes Res Clin Pract 2011, 93:10-16.
16. Xiao Y., Xu A., Law L.S., Chen C., Li H., Li X., et al. Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J Clin Endocrinol Metab 2012, 97:E54-E58.
17. Mai K., Andres J., Biedasek K., Weicht J., Bobbert T., Sabath M., et al. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 2009, 58:1532-1538.
18. Mai K., Bobbert T., Groth C., Assmann A., Meinus S., Kraatz J., et al. Physiological modulation of circulating FGF21: relevance of free fatty acids and insulin. Am J Physiol Endocrinol Metab 2010, 299:E126-E130.
19. Vienberg S.G., Brons C., Nilsson E., Astrup A., Vaag A., Andersen B. Impact of short-term high-fat feeding and insulin-stimulated FGF21 levels in subjects with low birth weight and controls. Eur J Endocrinol 2012, 167:49-57.
20. Straczkowski M., Karczewska-Kupczewska M., Adamska A., Otziomek E., Kowalska I., Nikolajuk A. Serum fibroblast growth factor 21 in human obesity: regulation by insulin infusion and relationship with glucose and lipid oxidation. Int J Obes (Lond) 2013, 37:1386-1390.
21. Fisher F.M., Chui P.C., Antonellis P.J., Bina H.A., Kharitonenkov A., Flier J.S., et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010, 59:2781-2789.
22. Gaich G., Chien J.Y., Fu H., Glass L.C., Deeg M.A., Holland W.L., et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013, 18:333-340.
23. Adams A.C., Cheng C.C., Coskun T., Kharitonenkov A. FGF21 requires betaklotho to act in vivo. PLoS ONE 2012, 7:e49977.
24. Diaz-Delfin J., Hondares E., Iglesias R., Giralt M., Caelles C., Villarroya F. TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 2012, 153:4238-4245.
25. So W.Y., Cheng Q., Chen L., Evans-Molina C., Xu A., Lam K.S., et al. High glucose represses beta-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor gamma signaling. Diabetes 2013, 62:3751-3759.
26. Tyynismaa H., Raivio T., Hakkarainen A., Ortega-Alonso A., Lundbom N., Kaprio J., et al. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab 2011, 96:E351-E355.
27. Mitka M. Diabetes group warns vascular complication is underdiagnosed and undertreated. JAMA 2004, 291:809-810.
28. Jian W.X., Peng W.H., Jin J., Chen X.R., Fang W.J., Wang W.X., et al. Association between serum fibroblast growth factor 21 and diabetic nephropathy. Metabolism 2012, 61:853-859.
29. Crasto C., Semba R.D., Sun K., Ferrucci L. Serum fibroblast growth factor 21 is associated with renal function and chronic kidney disease in community-dwelling adults. J Am Geriatr Soc 2012, 60:792-793.
30. Stein S., Bachmann A., Lossner U., Kratzsch J., Bluher M., Stumvoll M., et al. Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 2009, 32:126-128.
31. Stein S., Stepan H., Kratzsch J., Verlohren M., Verlohren H.J., Drynda K., et al. Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism 2010, 59:33-37.
32. Kuro O.M. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol 2013, 9:650-660.
33. Lin Z., Zhou Z., Liu Y., Gong Q., Yan X., Xiao J., et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS ONE 2011, 6:e18398.
34. Kim H.W., Lee J.E., Cha J.J., Hyun Y.Y., Kim J.E., Lee M.H., et al. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice. Endocrinology 2013, 154:3366-3376.
35. Loeffler I., Hopfer U., Koczan D., Wolf G. Type VIII collagen modulates TGF-beta1-induced proliferation of mesangial cells. J Am Soc Nephrol 2011, 22:649-663.
36. Chow W.S., Xu A., Woo Y.C., Tso A.W., Cheung S.C., Fong C.H., et al. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013, 33:2454-2459.
37. Lenart-Lipinska M., Matyjaszek-Matuszek B., Gernand W., Nowakowski A., Solski J. Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up. Diabetes Res Clin Pract 2013, 101:194-200.
38. Ong K.L., Januszewski A.S., O'Connell R., Jenkins A.J., Xu A., Sullivan D.R., et al. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia 2015, 58:464-473.
39. Planavila A., Redondo-Angulo I., Ribas F., Garrabou G., Casademont J., Giralt M., et al. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res 2014.
40. Rena G., Pearson E.R., Sakamoto K. Molecular mechanism of action of metformin: old or new insights. Diabetologia 2013, 56:1898-1906.
41. Kim K.H., Jeong Y.T., Kim S.H., Jung H.S., Park K.S., Lee H.Y., et al. Metformin-induced inhibition of the mitochondrial respiratory chain increases FGF21 expression via ATF4 activation. Biochem Biophys Res Commun 2013, 440:76-81.
42. Nygaard E.B., Vienberg S.G., Orskov C., Hansen H.S., Andersen B. Metformin stimulates FGF21 expression in primary hepatocytes. Exp Diabetes Res 2012, 2012:465282.
43. Ong K.L., Rye K.A., O'Connell R., Jenkins A.J., Brown C., Xu A., et al. Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J Clin Endocrinol Metab 2012, 97:4701-4708.
44. Eto K., Tumenbayar B., Nagashima S., Tazoe F., Miyamoto M., Takahashi M., et al. Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. Diabetes Res Clin Pract 2010, 89:52-57.
45. Lin Z., Tian H., Lam K.S., Lin S., Hoo R.C., Konishi M., et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 2013, 17:779-789.
46. Qiang L., Accili D. FGF21 and the second coming of PPARgamma. Cell 2012, 148:397-398.
47. Dutchak P.A., Katafuchi T., Bookout A.L., Choi J.H., Yu R.T., Mangelsdorf D.J., et al. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148:556-567.
48. Samson S.L., Sathyanarayana P., Jogi M., Gonzalez E.V., Gutierrez A., Krishnamurthy R., et al. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia 2011, 54:3093-3100.
49. Adams A.C., Halstead C.A., Hansen B.C., Irizarry A.R., Martin J.A., Myers S.R., et al. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS ONE 2013, 8:e65763.
50. Camacho R.C., Zafian P.T., Achanfuo-Yeboah J., Manibusan A., Berger J.P. Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice. Eur J Pharmacol 2013, 715:41-45.
51. Huang Z., Wang H., Lu M., Sun C., Wu X., Tan Y., et al. A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol. PLoS ONE 2011, 6:e20669.
52. Mu J., Pinkstaff J., Li Z., Skidmore L., Li N., Myler H., et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 2012, 61:505-512.
53. Hecht R., Li Y.S., Sun J., Belouski E., Hall M., Hager T., et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS ONE 2012, 7:e49345.
54. Kharitonenkov A., Beals J.M., Micanovic R., Strifler B.A., Rathnachalam R., Wroblewski V.J., et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS ONE 2013, 8:e58575.
55. Foltz I.N., Hu S., King C., Wu X., Yang C., Wang W., et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci Transl Med 2012, 4:162ra153.
56. Wu A.L., Kolumam G., Stawicki S., Chen Y., Li J., Zavala-Solorio J., et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med 2011, 3:113ra126.
57. Holland W.L., Adams A.C., Brozinick J.T., Bui H.H., Miyauchi Y., Kusminski C.M., et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab 2013, 17:790-797.
58. Sarruf D.A., Thaler J.P., Morton G.J., German J., Fischer J.D., Ogimoto K., et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 2010, 59:1817-1824.
59. Xu J., Lloyd D.J., Hale C., Stanislaus S., Chen M., Sivits G., et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58:250-259.
60. Lauer M.S. Lemons for obesity. Ann Intern Med 2012, 157:139-140.
61. Cho S.W., Yang J.Y., Her S.J., Choi H.J., Jung J.Y., Sun H.J., et al. Osteoblast-targeted overexpression of PPARgamma inhibited bone mass gain in male mice and accelerated ovariectomy-induced bone loss in female mice. J Bone Miner Res 2011, 26:1939-1952.
62. Wei W., Dutchak P.A., Wang X., Ding X., Bookout A.L., Goetz R., et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A 2012, 109:3143-3148.
63. Inagaki T., Lin V.Y., Goetz R., Mohammadi M., Mangelsdorf D.J., Kliewer S.A. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab 2008, 8:77-83.
64. William R., Hiatt M.D., Robert J., Smith M.D. Assessing the clinical benefits of lipid-disorder drugs. N Engl J Med 2014, 370:396-399.
65. Lee P., Linderman J., Smith S., Brychta R.J., Perron R., Idelson C., et al. Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans?. Osteoporos Int 2013, 24:3053-3057.
66. Adams A.C., Kharitonenkov A. FGF21: The center of a transcriptional nexus in metabolic regulation. Curr Diabetes Rev 2012, 8:285-293.